BridgeMD
New treatment option for Prostate Cancer (Post Prostatectomy)
Official title Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP
ClinicalTrials.gov ID: NCT07607990
What this study is testing
- What it's testing
- The postoperative incidence of catheter-related bladder discomfort (CRBD) ranges from 47% to 95%. It increases postoperative pain and agitation, thus requiring early intervention.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80, men only
You may be able to join if
- Aged 18 to 80 years old (inclusive);
- American Society of Anesthesiologists (ASA) physical status classification Class I-III;
- Undergoing elective laparoscopic radical prostatectomy under general anesthesia;
- Having a clear understanding of the study, voluntarily participating, and providing informed consent signed by themselves or their family members.
You likely can't join if
- Pre-existing bladder diseases, such as overactive bladder (frequency of micturition \> 3 times per night or \> 8 times within 24 hours), neurogenic...
- Postoperative status of pelvic organs or spine that affects bladder function;
- Postoperative status of total proctocolectomy;
- Severe cardiac insufficiency (activity tolerance \< 4 METs) or clearly diagnosed coronary heart disease;
- Clearly diagnosed chronic obstructive pulmonary disease (COPD) or a history of asthma;
- Hepatic insufficiency with Child-Pugh Class C;
See the full eligibility criteria
- Aged 18 to 80 years old (inclusive);
- American Society of Anesthesiologists (ASA) physical status classification Class I-III;
- Undergoing elective laparoscopic radical prostatectomy under general anesthesia;
- Having a clear understanding of the study, voluntarily participating, and providing informed consent signed by themselves or their family members.
- Pre-existing bladder diseases, such as overactive bladder (frequency of micturition \> 3 times per night or \> 8 times within 24 hours), neurogenic bladder, and bladder outlet obstruction;
- Postoperative status of pelvic organs or spine that affects bladder function;
- Postoperative status of total proctocolectomy;
- Severe cardiac insufficiency (activity tolerance \< 4 METs) or clearly diagnosed coronary heart disease;
- Clearly diagnosed chronic obstructive pulmonary disease (COPD) or a history of asthma;
- Hepatic insufficiency with Child-Pugh Class C;
- Chronic kidney disease requiring dialysis;
- Active peptic ulcer/hemorrhagic disease;
- Body mass index (BMI) ≤ 18 kg/m² or ≥ 28 kg/m²;
- Chronic analgesic abuse;
- Use of other nonsteroidal anti-inflammatory drugs (NSAIDs) within one week;
- Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs);
- Mental or neurological disorders that prevent the completion of rating scales; or cognitive impairment resulting in the loss of capacity for civil conduct.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.